US 11,938,188 B2
Injectable slurries and methods of manufacturing and using the same
Lilit Garibyan, Newton, MA (US); Richard Rox Anderson, Boston, MA (US); William A. Farinelli, Boston, MA (US); and Emilia Javorsky, Watertown, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US)
Filed on Mar. 1, 2021, as Appl. No. 17/188,359.
Application 17/188,359 is a continuation of application No. 15/505,042, abandoned, previously published as PCT/US2015/047301, filed on Aug. 27, 2015.
Claims priority of provisional application 62/121,329, filed on Feb. 26, 2015.
Claims priority of provisional application 62/121,472, filed on Feb. 26, 2015.
Claims priority of provisional application 62/042,979, filed on Aug. 28, 2014.
Prior Publication US 2021/0244817 A1, Aug. 12, 2021
Int. Cl. A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 31/045 (2006.01); A61K 31/047 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/245 (2006.01); A61K 31/445 (2006.01); A61K 31/7004 (2006.01); A61K 31/718 (2006.01); A61K 31/765 (2006.01); A61K 33/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/28 (2006.01)
CPC A61K 45/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 31/045 (2013.01); A61K 31/047 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/245 (2013.01); A61K 31/445 (2013.01); A61K 31/7004 (2013.01); A61K 31/718 (2013.01); A61K 31/765 (2013.01); A61K 33/00 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/26 (2013.01); A61K 47/28 (2013.01)] 19 Claims
 
1. A slurry configured for injection into a target tissue comprising:
a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm, wherein the plurality of sterile ice particles are substantially uniform in shape; and
a biocompatible surfactant, wherein the biocompatible surfactant is glycerol;
the slurry having a mean temperature in the range of about 0° C. to about −15° C.;
wherein the target tissue is selected from the group consisting of adipose tissue and a myelinated nerve; and
wherein the slurry is configured to cause the target tissue to reach a temperature in the range of about −8° C. to about 0° C. such that crystallization occurs in the target tissue and the crystallization causes localized and selective damage to the target tissue.